MedTrace Logo

Safety and Efficacy Study of BMS-823778 to Treat Uncontrolled High Blood Pressure in Overweight and Obese Patients

NCT01602367 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2015-10-12

No results posted yet for this study

Summary

The purpose of this study is to determine whether BMS-823778 is safe and effective in the treatment of hypertension in overweight and obese patients.

Conditions

Interventions

DRUG

BMS-823778

Capsules, Oral, 2 mg, Once daily, 12 weeks

DRUG

BMS-823778

Capsules, Oral, 6 mg, Once daily, 12 weeks

DRUG

BMS-823778

Capsules, Oral, 15 mg, Once daily, 12 weeks

DRUG

Placebo matching with BMS-823778

Capsules, Oral, 0 mg, Once daily, 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • United States
  • Colombia
  • Hungary
  • Puerto Rico
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01602367 on ClinicalTrials.gov